Fusion Pharmaceuticals Inc FUSN

NAS: FUSN | ISIN: CA36118A1003   3/05/2024
21,45 USD (-0,19%)
(-0,19%)   3/05/2024

25 april 2024 · Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order · Persbericht

9 april 2024 · Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024 · Persbericht

27 maart 2024 · INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Fusion Pharmaceuticals Inc. - FUSN · Persbericht

20 maart 2024 · Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates · Persbericht

19 maart 2024 · Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer · Persbericht

6 maart 2024 · Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

5 maart 2024 · Fusion Pharmaceuticals to Present Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the 2024 AACR Annual Meeting · Persbericht

26 februari 2024 · Fusion Pharmaceuticals to Present at Upcoming March Investor Conferences · Persbericht

16 februari 2024 · Fusion Pharmaceuticals Enters into Exclusive Worldwide License Agreement with Heidelberg University and Euratom for Actinium-Based PSMA Targeted Radiotherapy · Persbericht

7 februari 2024 · Fusion Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference · Persbericht

6 februari 2024 · Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

4 januari 2024 · Fusion Pharmaceuticals Announces Clinical Program and Manufacturing Updates · Persbericht

8 november 2023 · Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

8 november 2023 · Fusion Pharmaceuticals to Present at Upcoming Investor Conferences · Persbericht

7 november 2023 · Fusion Pharmaceuticals Announces Third Quarter 2023 Financial Results and Clinical Program Updates · Persbericht

16 oktober 2023 · Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors · Persbericht

12 oktober 2023 · Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting FPI-2068, a Novel Targeted Alpha Therapy for EGFR-cMET Expressing Cancers · Persbericht

6 september 2023 · Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

5 september 2023 · Fusion Pharmaceuticals to Present at Upcoming September Investor Conferences · Persbericht

9 augustus 2023 · Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

Mijn selecties